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Anticonvulsant Pharmacokinetics
Variations in the concentration of anticonvulsant drugs at receptor sites within the brain depend on the dose administered, and differences in pharmacokinetic parameters such as absorption, distribution and rate of metabolism and elimination of the drugs concerned. Plasma concentrations may be monitored and dose adjustments made to achieve plasma concentrations which will result in maximal anticonvulsant effect and minimum toxicity. In animal studies, the plasma concentration bears a good correlation with brain concentration (Rizzo et al. 1972) , while in man CSF concentrations of diphenylhydantoin (DPH) are approximately 10% of plasma concentration (Lund et al. 1972) .
Variations between individuals in DPH absorption have been reported; peak plasma concentrations occurring between three and twelve hours after drug administration (O'Malley et al. 19069) . A relatively common cause of failure to achieve a therapeutic plasma concentration is failure of ingestion of the drug. Variation in formulations may also contribute to differences in its availability in vivo. Once absorbed, approximately 90% of DPH is bound to plasma proteins (albumin and a-globulin) at the usual therapeutic plasma concentrations (Lund et al. 1972) . The 10 % which is free corresponds to the concentration found in the CSF. Free drug gains access to many tissues; in liver, brain and muscle it is bound to nucleoproteins within the endoplasmic reticulum (Kemp & Woodbury 1971). The apparent volume of distribution is high, ranging from 0.4 to 1.1 litre per kg in volunteers (Thor-geirsson 1972) . DPH is eliminated by microsomal hydroxylation, the plasma half-life ranges from seven to seventy hours, but this is dose dependent, and at high plasma concentrations the decay follows zero order rather than first order kinetics (Arnold & Berber 1970) . Less than 5% of DPH is excreted unchanged, the main metabolite in urine is 5-(p hydroxyphenyl)-5-phenylhydantoin (HPPH) (Butler 1957). There is no evidence that DPH stimulates its own rate of elimination at low plasma concentrations, because plasma concentrations remain constant on continuous dosing in individual patients. Diphenylhydantoin administration does, however, cause increased urine excretion of 6/3 hydroxycortisol (Cucinell et al. 1963 ), a polar metabolite of cortisol formed in the endoplasmic reticulum, but this may be due to alteration of cortisol secretion rather than alteration of the pattern of elimination of cortisol.
Drug interactions with DPH
Rather less is known about the pharmacokinetics of phenobarbitone in man. It is well absorbed, but there are wide variations in the rate of absorption, possibly attributable to differences in gastric emptying. Over a range of concentrations of 20 to 100 ,ug/ml, approximately 40% of phenobarbitone is bound to plasma albumin (Waddell & Butler 1957) . The apparent volume of distribution is approximately 60% of body weight. Its rate of distribution to the brain in experimental animals and presumably in man is slow; in animals it gains access to grey matter before white matter. Like DPH, phenobarbitone will cross the placental barrier and enter the fetus (Waddell & Butler 1957) . The rate of elimination of phenobarbitone is slow, the plasma half-life ranging from 50 to 140 hours. Between 25 % and 40 % of the dose, however, is excreted in urine unchanged (Maynert & van Dyke 1949) . The wide range between individuals in these parameters in part accounts for the difference in response seen, when these drugs are administered to groups of patients. Anticonvulsant drugs, given in high dosage in the treatment of epilepsy, may produce hypocalciemia and more rarely rickets or osteomalacia. These disturbances are illustrated in 3 patients with seizures, who were treated with anticonvulsant drugs; 2 of them developed rickets (or osteomalacia) and the third was eventually diagnosed as idiopathic hypoparathyroidism. The relief of hypocalclmia by vitamin D in long-term anticonvulsant therapy may reduce the severity of seizures and thus reduce the requirement for 
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Case Reports
Case 1 A boy of Asian origin, aged 8, was admitted to the metabolic ward in August 1970 with a history of grand-mal epilepsy since the age of 4i years. At the age of 6 years 3 months he was found to be underweight, rickets was diagnosed, and he was treated for two years with calciferol 1000 iu daily in a residential school. At the end of this time he had developed skeletal deformities and in January 1970 his dose of calciferol was raised to 1600 iu daily after two additional doses of 15000 iu. On admission, he was also receiving phenytoin 50 mg twice daily, primidone 250 mg three times daily and ethosuximide 250 mg twice daily. On examination, he was below the third percentile for both height and weight. He had a right genu valgum and a left genu varum with a 6 cm gap between his medial malleoli. Anticonvulsant rickets was diagnosed after excluding other known causes. He was discharged and vitamin D2 0.25 mg on alternate days was prescribed. This dosage was just sufficient to heal his rickets slowly; progress in his clinical and laboratory findings is illustrated in Fig l. His anticonvulsant therapy was controlled independently elsewhere and it was found that the dosage could be materially reduced without deterioration in his epilepsy.
